^
BIOMARKER:

KIF5B-RET fusion

i
Other names: KIF5B, Kinesin Family Member 5B, Conventional Kinesin Heavy Chain, Ubiquitous Kinesin Heavy Chain, Kinesin-1 Heavy Chain, KNS1, UKHC, KNS, Epididymis Secretory Protein Li 61, Kinesin 1 (110-120kD), Kinesin Heavy Chain, HEL-S-61, KINH, RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (
Entrez ID:
KIF5B-RET fusion
NSCLC
RXDX-105
Sensitive: C3 – Early Trials
KIF5B-RET fusion
NSCLC
lenvatinib
Sensitive: C3 – Early Trials
KIF5B-RET fusion
NSCLC
sunitinib
Sensitive: C3 – Early Trials
KIF5B-RET fusion
NSCLC
vandetanib
Sensitive: C3 – Early Trials
KIF5B-RET fusion
NSCLC
nintedanib
Sensitive: C3 – Early Trials
KIF5B-RET fusion
NSCLC
cabozantinib capsule
Sensitive: C3 – Early Trials
KIF5B-RET fusion
Lung Cancer
alectinib
Resistant: C3 – Early Trials
KIF5B-RET fusion
LUAD
nivolumab
Sensitive: C4 – Case Studies
KIF5B-RET fusion
NSCLC
pembrolizumab
Resistant: C4 – Case Studies
KIF5B-RET fusion
NSCLC
selpercatinib
Resistant: C4 – Case Studies
KIF5B-RET fusion
LUAD
everolimus + vandetanib
Sensitive: C4 – Case Studies
KIF5B-RET fusion
NSCLC
cabozantinib tablet
Resistant: C4 – Case Studies
KIF5B-RET fusion
LUAD
cabozantinib tablet
Sensitive: D – Preclinical
KIF5B-RET fusion
LUAD
vandetanib
Sensitive: D – Preclinical
KIF5B-RET fusion
NSCLC
pralsetinib
Sensitive: D – Preclinical